Hemera Biosciences

Medford, United States Founded: 2010 • Age: 16 yrs
Anti-complement gene therapies for AMD treatment are developed pre-clinically.

About Hemera Biosciences

Hemera Biosciences is a Healthcare company based in Medford (United States) founded in 2010. Anti-complement gene therapies for AMD treatment are developed pre-clinically. Hemera Biosciences has raised $3.75 million across 1 funding round. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.

Company details

Hemera Biosciences was founded in 2010 and is based in Medford, United States. Focus is placed on the biotechnology sector, where anti-complement gene-based therapies are developed for dry and wet age-related macular degeneration (AMD). This condition represents the primary cause of blindness in older adults, with no options available for 90 of dry AMD cases. Preclinical models have shown reductions in complement-mediated damage to eye tissues through proprietary recombinant molecules.

  • Headquarters Medford, United States
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website hemerabiosciences.com
  • Social LinkedIn X
Key Metrics
  • Total Equity Funding
    $3.75M (USD)

    in 1 rounds

  • Latest Funding Round
    $3.75M (USD), Series A

    Apr 2013

Funding Insights of Hemera Biosciences

Hemera Biosciences has successfully raised a total of $3.75M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.75 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $3.75M
  • Total Rounds 1
  • Last Round Series A β€” $3.75M
  • First Round $3.75M

    (Apr 2013)

All 1 funding rounds of Hemera Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2013$3.75MSeries A––
–

People of Hemera Biosciences

1 people are tracked at Hemera Biosciences (1 in leadership).

NameRoleGroup
Adam Rogers
Chief Executive Officer and FounderLeadership
Premium access

Complete people profiles for Hemera Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Hemera Biosciences

2 dated milestones of Hemera Biosciences across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Hemera Biosciences is founded.
  2. Funding First funding round of $3.8M.

Competitors of Hemera Biosciences

Hemera Biosciences has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
insitro.com2018San Francisco, United States$643.21M257
An AI-enabled platform is developed for infectious disease treatment.
bridgebio.com2015Palo Alto, United States$434.2M
Therapeutics for genetic diseases are developed through targeted interventions.
forgebiologics.com2020Columbus, United States$250M118
Gene therapies for rare diseases are developed to treat patients.
Premium access

Detailed competitors of Hemera Biosciences

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Hemera Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Hemera Biosciences

Premium access

Complete news archive for Hemera Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hemera Biosciences

Hemera Biosciences was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Hemera Biosciences is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.

Hemera Biosciences is a funded company, having raised a total of $3.75M across 1 funding round to date. The company's 1st funding round was a Series A of $3.75M, raised on Apr 2013.

Hemera Biosciences was founded in 2010 and is based in Medford, United States. Focus is placed on the biotechnology sector, where anti-complement gene-based therapies are developed for dry and wet age-related macular degeneration (AMD). This condition represents the primary cause of blindness in older adults, with no options available for 90 of dry AMD cases. Preclinical models have shown reductions in complement-mediated damage to eye tissues through proprietary recombinant molecules.

Hemera Biosciences's top competitors include BridgeBio, Forge Biologics and Insitro.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available